Ask AI
Lung Cancer Highlights From ASCO 2026

CE / CME

Lung Cancer Highlights From ASCO 2026: Expert Perspectives on Emerging Practice-Changing Data

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: July 31, 2026

Expiration: January 30, 2028

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with lung cancer do you provide care for in a typical week? 

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Based on results presented from the phase III LIBRETTO-432 trial of adjuvant selpercatinib at ASCO 2026, what would you tell a patient with early-stage RET fusion–positive NSCLC about the reported event-free survival at 24 months?

4.

Which of the following was shown in a post hoc analysis of outcomes from the phase III IMforte trial of first-line maintenance therapy with atezolizumab plus lurbinectedin compared with atezolizumab alone in patients with extensive-stage SCLC and at least stable disease after 4 cycles of atezolizumab plus platinum-based chemotherapy?